Sign in

    Brian

    Senior Managing Director in Investment Banking at Leerink Partners

    Brian Swanson is a Senior Managing Director in Investment Banking at Leerink Partners, specializing in biopharma sector transactions. He has executed over 100 M&A and capital markets deals for public and private biopharma companies, advising names such as Gilead and other leading biotechnology firms while consistently delivering value through high-profile transactions. Swanson began his career as a management consultant at PwC before joining Leerink Partners in 2014, and holds an M.B.A. from Cornell University and a B.S. from Stanford University. He has established himself as an expert in biopharma banking with a proven track record in executing complex deals and is based in New York.

    Brian's questions to ARROWHEAD PHARMACEUTICALS (ARWR) leadership

    Brian's questions to ARROWHEAD PHARMACEUTICALS (ARWR) leadership • Q2 2025

    Question

    Brian, on behalf of Mani Faroohar at Leerink Partners, asked about the recent paydown of the company's credit facility and whether this trend is expected to continue.

    Answer

    Outgoing CFO Ken Myszkowski explained that the recent paydown was a required one-time event triggered by the cash received from the Sarepta agreement. He clarified that future payments are only required when the company receives cash inflows from milestones, not on a regular schedule.

    Ask Fintool Equity Research AI